Relationships between serum levels of thyroid hormones and serum concentrations of asymmetric dimethylarginine (ADMA) and N-terminal-pro-B-type natriuretic peptide (NT-proBNP) in patients with Graves' disease

Endocrine

Volumn 39, Issue 3, 2011, Pages 266-271

  Gu, Li Qun ^a   Zhao, Lin ^a   Zhu, Wei ^a   Li, Feng Ying ^a   Zhang, Min Jia ^a   Liu, Yun ^a   Liu, Jian Min ^a   Ning, Guang ^a   Zhao, Yong Ju ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

ADMA; Graves' disease; Hyperthyroidism; NT proBNP

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; N(G),N(G) DIMETHYLARGININE; THYROID HORMONE;

ADULT; AMINO ACID BLOOD LEVEL; ARTICLE; BLOOD PRESSURE; BODY MASS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; FEMALE; GRAVES DISEASE; HEART RATE; HUMAN; HYPERTHYROIDISM; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEX DIFFERENCE; THYROID HORMONE BLOOD LEVEL;

EID: 79959930096     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-011-9436-7     Document Type: Article

References (34)

1. I. Klein, S. Danzi, Thyroid disease and the heart. Circulation 116, 1725-1735(2007) (Pubitemid 47537847)
2. V. Fonseca, C. Desouza, S. Asnani, I. Jialal, Nontraditional risk factors for cardiovascular disease in diabetes. Endocr. Rev. 25, 153-175(2004) (Pubitemid 38269978)
3. S. Moncada, A. Higgs, The L-arginine-nitric oxide pathway. N. Engl. J. Med. 329, 2002-2012(1993) (Pubitemid 24015045)
4. R. H. Boger, Asymmetric dimethylarginine (ADMA): A novel risk marker in cardiovascular medicine and beyond. Ann. Med. 38, 126-136(2006)
5. J. T. Kielstein, C. Zoccali, Asymmetric dimethylarginine: a cardiovascular risk factor and a uremic toxin coming of age? Am. J. Kidney Dis. 46, 186-202(2005) (Pubitemid 41040347)
6. M. Akturk, A. Altinova, I. Mert, A. Dincel, A. Sargin, U. Buyukkagnici, M. Arslan, N. Danisman, Asymmetric dimethylarginine concentrations are elevated in women with gestational diabetes. Endocrine 38, 134-141(2010)
7. F. Mittermayer, K. Krzyzanowska, M. Exner, W. Mlekusch, J. Amighi, S. Sabeti, E. Minar, M. Muller, M. Wolzt, M. Schillinger, Asymmetric dimethylarginine predicts major adverse cardiovascular events in patients with advanced peripheral artery disease. Arterioscler. Thromb. Vasc. Biol 26, 2536-2540(2006) (Pubitemid 44607477)
8. R. H. Boger, L. M. Sullivan, E. Schwedhelm, T. J. Wang, R. Maas, E. J. Benjamin, F. Schulze, V. Xanthakis, R. A. Benndorf, R. S. Vasan, Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community. Circulation 119, 1592-1600(2009)
9. H. Paiva, M. Kahonen, T. Lehtimaki, G. Alfthan, J. Viikari, R. Laaksonen, N. Hutri-Kahonen, T. Laitinen, L. Taittonen, O. T. Raitakari, M. Juonala, Levels of asymmetrical dimethylarginine are predictive of brachial artery flow-mediated dilation 6 years later. The cardiovascular risk in young Finns study. Atherosclerosis 212, 512-515(2010)
10. A. Clerico, F. A. Recchia, C. Passino, M. Emdin, Cardiac endocrine function is an essential component of the homeostatic regulation network: physiological and clinical implications. Am. J. Physiol. Heart Circ. Physiol. 290, H17-H29 (2006)
11. Y. K. Kim, S. J. Shin, S. H. Ihm, C. S. Park, H. Y. Kim, T. Y. Hong, H. C. Song, C. W. Yang, Y. S. Kim, E. J. Choi, Longitudinal changes of left ventricular filling pressure and N-terminal probrain natriuretic peptide on chronic hemodialysis. Clin. Nephrol. 74, 190-197(2010)
12. M. Brueckmann, G. Huhle, S. Lang, K. K. Haase, T. Bertsch, C. Weiss, J. J. Kaden, C. Putensen, M. Borggrefe, U. Hoffmann, Prognostic value of plasma N-terminal pro-brain natriuretic peptide in patients with severe sepsis. Circulation 112, 527-534(2005) (Pubitemid 41060793)
13. J. P. Goetze, Biochemistry of pro-B-type natriuretic peptidederived peptides: the endocrine heart revisited. Clin. Chem. 50, 1503-1510(2004) (Pubitemid 39121217)
14. G. Bodlaj, R. Pichler, W. Brandstatter, M. Hatzl-Griesenhofer, W. Maschek, G. Biesenbach, J. Berg, Hyperthyroidism affects arterial stiffness, plasma NT-pro-B-type natriuretic peptide levels, and subendocardial perfusion in patients with Graves' disease. Ann. Med. 39, 608-616(2007) (Pubitemid 350175307)
15. P. J. Owen, R. Sabit, J. H. Lazarus, Thyroid disease and vascular function. Thyroid 17, 519-524(2007) (Pubitemid 47068113)
16. J. Burggraaf, S. Lalezari, J. J. Emeis, U. M. Vischer, P. H. de Meyer, H. Pijl, A. F. Cohen, Endothelial function in patients with hyperthyroidism before and after treatment with propranolol and thiamazol. Thyroid 11, 153-160(2001) (Pubitemid 32221038)
17. H. Volzke, D. M. Robinson, U. Schminke, J. Ludemann, R. Rettig, S. B. Felix, C. Kessler, U. John, W. Meng, Thyroid function and carotid wall thickness. J. Clin. Endocrinol. Metab. 89, 2145-2149(2004) (Pubitemid 38619844)
18. C. Hermenegildo, P. Medina, M. Peiro, G. Segarra, J. M. Vila, J. Ortega, S. Lluch, Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in hyperthyroid patients. J. Clin. Endocrinol. Metab. 87, 5636-5640(2002) (Pubitemid 36034371)
19. E. Arikan, C. H. Karadag, S. Guldiken, Asymmetric dimethylarginine levels in thyroid diseases. J. Endocrinol. Invest. 30, 186-191(2007) (Pubitemid 46929316)
20. M. Schultz, C. Kistorp, B. Langdahl, I. Raymond, P. Hildebrandt, J. Faber, N-terminal-pro-B-type natriuretic peptide in acute hyperthyroidism. Thyroid 17, 237-241(2007) (Pubitemid 46557372)
21. S. Arikan, A. Tuzcu, D. Gokalp, M. Bahceci, R. Danis, Hyperthyroidism may affect serum N-terminal pro-B-type natriuretic peptide levels independently of cardiac dysfunction. Clin. Endocrinol. 67, 202-207(2007) (Pubitemid 47076292)
22. M. Schultz, J. Faber, C. Kistorp, A. Jarlov, F. Pedersen, N. Wiinberg, P. Hildebrandt, N-terminal-pro-B-type natriuretic peptide (NT-pro-BNP) in different thyroid function states. Clin. Endocrinol. 60, 54-59(2004) (Pubitemid 38183498)
23. I. Klein, K. Ojamaa, Thyroid hormone and the cardiovascular system. N. Engl. J. Med. 344, 501-509(2001) (Pubitemid 32164903)
24. Y. Li, H. Chen, J. Tan, X. Wang, H. Liang, X. Sun, Impaired release of tissue plasminogen activator from the endothelium in Graves' disease-indicator of endothelial dysfunction and reduced fibrinolytic capacity. Eur. J. Clin. Invest. 28, 1050-1054(1998) (Pubitemid 29050141)
25. I. M. Colin, P. Kopp, J. Zbaren, A. Haberli, W. E. Grizzle, J. L. Jameson, Expression of nitric oxide synthase III in human thyroid follicular cells: evidence for increased expression in hyperthyroidism. Eur. J. Endocrinol. 136, 649-655(1997) (Pubitemid 27286553)
26. L. J. Millatt, A. P. Johnstone, S. S. Nussey, G. S. Whitley, Thyrocyte release of asymmetric dimethylarginine does not account for human thyrocyte inhibition of endothelial cell cyclic GMP. Eur. J. Endocrinol. 142, 493-499(2000) (Pubitemid 30341182)
27. B. Wojciak-Stothard, B. Torondel, L. Y. Tsang, I. Fleming, B. Fisslthaler, J. M. Leiper, P. Vallance, The ADMA/DDAH pathway is a critical regulator of endothelial cell motility. J. Cell Sci. 120, 929-942(2007) (Pubitemid 46638508)
28. J. T. Kielstein, F. Donnerstag, S. Gasper, J. Menne, A. Kielstein, J. Martens-Lobenhoffer, F. Scalera, J. P. Cooke, D. Fliser, S. M. Bode-Boger, ADMA increases arterial stiffness and decreases cerebral blood flow in humans. Stroke 37, 2024-2029(2006) (Pubitemid 44309898)
29. S. N. Mamatha, D. Nagaraja, M. Philip, R. Christopher, Asymmetric dimethylarginine as a risk marker for early-onset ischemic stroke in Indian population. Clin. Chim. Acta 412, 139-142(2011)
30. R. H. Boger, R. Maas, F. Schulze, E. Schwedhelm, Asymmetric dimethylarginine (ADMA) as a prospective marker of cardiovascular disease and mortality-an update on patient populations with a wide range of cardiovascular risk. Pharmacol. Res. 60, 481-487(2009)
31. B. Ozmen, D. Ozmen, Z. Parildar, I. Mutaf, O. Bayindir, Serum N-terminal-pro-B-type natriuretic peptide (NT-pro-BNP) levels in hyperthyroidism and hypothyroidism. Endocr. Res. 32, 1-8(2007)
32. F. Liang, P. Webb, A. Marimuthu, S. Zhang, D. G. Gardner, Triiodothyronine increases brain natriuretic peptide (BNP) gene transcription and amplifies endothelin-dependent BNP gene transcription and hypertrophy in neonatal rat ventricular myocytes. J. Biol. Chem 278, 15073-15083(2003) (Pubitemid 36799841)
33. J. H. Rutten, F. U. Mattace-Raso, G. C. Verwoert, J. Lindemans, A. Hofman, J. C. Witteman, A. H. van den Meiracker, Arterial stiffness as determinant of increased amino terminal pro-B-type natriuretic peptide levels in individuals with and without cardiovascular disease-the Rotterdam study. J. Hypertens. 28, 2061-2067(2010)
34. K. B. Shah, W. J. Kop, R. H. Christenson, D. B. Diercks, D. Kuo, S. Henderson, K. Hanson, C. R. deFilippi, Post-discharge changes in NT-proBNP and quality of life after acute dyspnea hospitalization as predictors of one-year outcomes. Clin. Biochem. 43, 1405-1410(2010)